Last reviewed · How we verify
polyvalent melanoma vaccine
At a glance
| Generic name | polyvalent melanoma vaccine |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (PHASE3)
- Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma (PHASE2)
- Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma (PHASE2)
- Vaccine Therapy in Treating Patients With Malignant Melanoma (PHASE2)
- Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma (PHASE2)
- Vaccine Therapy for Patients With Stage III Melanoma (PHASE3)
- Vaccine Therapy for Patients With Stage IV Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polyvalent melanoma vaccine CI brief — competitive landscape report
- polyvalent melanoma vaccine updates RSS · CI watch RSS
- NYU Langone Health portfolio CI